<DOC>
	<DOCNO>NCT01697163</DOCNO>
	<brief_summary>This study base follow hypothesis `` De novo resistance EGFR-TKI EGFR mutation positive patient related mutation EGFR downstream gene '' . Investigators prospectively collect genomic DNA clinical data regard treatment outcomes EGFR-TKI NSCLC patient activate EGFR mutation . Investigators sequence candidate mutation EGFR downstream gene analyze c-met gene amplification protein expression PTEN , HGF , IGFR . To identify genetic mutation , amplification , protein expression predictive marker treatment outcomes , investigator analyze association treatment outcomes presence genetic alteration protein expression . Investigators attempt identify biomarkers able predict de novo resistance EGFR-TKI EGFR mutate NSCLC .</brief_summary>
	<brief_title>De Novo Resistance Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors</brief_title>
	<detailed_description>Investigators prospectively enroll patient match follow criterion : pathologically proven unresectable NSCLC , plan treat EGFR-TKI , patient activate EGFR mutation , available tissue sample DNA extraction .</detailed_description>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Pathologically proven unresectable NSCLC 2 . 20 year age old 3 . Planned treatment IressaÂ® 4 . Patients activate EGFR mutation ( del 19 , L858R ) 5 . Available detailed smoking history 6 . Available tissue sample ( archival tissue ) mutational molecular analysis ( representative paraffin block unstained section tumor diagnostic specimen mandatory ) 7 . Available blood sample 8 . At least one lesion measurable accord RECIST 1.1 criterion CT MRI 9 . Written inform consent 1 . More 3rd line treatment 2 . Previously treat EGFRTKI 3 . Life expectancy le 12 week 4 . Pregnant lactate female 5 . Any unresolved toxicity great CTC grade 2 ( version 4.0 ) previous anti cancer treatment . 6 . Unsuitable patient treatment determine doctor .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>De Novo Resistance</keyword>
	<keyword>Iressa</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>lung cancer</keyword>
</DOC>